Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial
Introduction: Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for g...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2016-08-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/8365/20965_CE(EK)_F(AK)_PF1(NEAK)_PFA(AK)_PF2(PAG).pdf |
| _version_ | 1818501238043443200 |
|---|---|
| author | Rohini Naineni Vishali Ravi Dwijendra Kocherlakota Subbaraya Jammula Surya Prasanna Veerendranath Reddy Panthula Rekha Rani Koduganti |
| author_facet | Rohini Naineni Vishali Ravi Dwijendra Kocherlakota Subbaraya Jammula Surya Prasanna Veerendranath Reddy Panthula Rekha Rani Koduganti |
| author_sort | Rohini Naineni |
| collection | DOAJ |
| description | Introduction: Alendronate (ALN), an aminobisphosphonate,
inhibits osteoclastic bone resorption and also stimulates
osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an
osteoconductive graft material which provides a scaffold for
bone formation and also a widely used drug delivery vehicle
for growth factors and antibiotics. Drug delivery vehicles, like
β-TCP, improve the potency of the drugs by specific local site
delivery of the drug, optimal release characteristics and easy
handling.
Aim: The aim of the this study was to evaluate the bone
formation potential of 400µg ALN delivered in β-TCP in the
treatment of periodontal intra-osseous defects.
Materials and Methods: Thirty patients with periodontal
defects were randomly assigned to 400µg ALN + β-TCP + Saline
(test) group and β-TCP + Saline (active-control) group. Clinical
parameters like Clinical Attachment Level (CAL) gain, Probing
Depth (PD) reduction, post-operative Gingival Recession (GR)
were assessed from the baseline, 3 months and 6 months
recordings. Radiographic parameters like Linear Bone Growth
(LBG), Percentage Bone Fill (%BF), and change in alveolar
crest height (ACH) were assessed from baseline and 6 months
radiographs.
Results: Mean measurements in the ALN test group for CAL gain
(3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ±
0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater
with a p-value <0.05 compared to the mean measurements of
CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm),
LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control
group. There was mild alveolar crestal apposition (0.32 ± 0.68
mm) in the ALN test group and mild alveolar crestal resorption
(-0.24 ± 0.40 mm) in the control group.
Conclusion: 400µg ALN combined with β-TCP bone graft
material was effective in improving soft tissue parameters,
inhibiting alveolar crestal resorption and enhancing bone
formation, compared to β-TCP alone. |
| first_indexed | 2024-12-10T20:53:27Z |
| format | Article |
| id | doaj.art-cb00e947ed2f437fa6948fc40c99cd84 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-10T20:53:27Z |
| publishDate | 2016-08-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-cb00e947ed2f437fa6948fc40c99cd842022-12-22T01:34:02ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2016-08-01108ZC113ZC11710.7860/JCDR/2016/20965.8365Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical TrialRohini Naineni0Vishali Ravi1Dwijendra Kocherlakota Subbaraya2Jammula Surya Prasanna3Veerendranath Reddy Panthula4Rekha Rani Koduganti5Reader, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre, Hyderabad, Telangana, India. Senior Lecturer, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre, Hyderabad, Telangana, India. Professor and Head, Department of Pedodontics, MNR Dental College and Hospital, Sangareddy, Telangana, India. Professor, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre, Hyderabad, Telangana, India.Professor, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre, Hyderabad, Telangana, India.Professor and Head, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre, Hyderabad, Telangana, India. Introduction: Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling. Aim: The aim of the this study was to evaluate the bone formation potential of 400µg ALN delivered in β-TCP in the treatment of periodontal intra-osseous defects. Materials and Methods: Thirty patients with periodontal defects were randomly assigned to 400µg ALN + β-TCP + Saline (test) group and β-TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs. Results: Mean measurements in the ALN test group for CAL gain (3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ± 0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm), LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 ± 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 ± 0.40 mm) in the control group. Conclusion: 400µg ALN combined with β-TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to β-TCP alone.https://jcdr.net/articles/PDF/8365/20965_CE(EK)_F(AK)_PF1(NEAK)_PFA(AK)_PF2(PAG).pdfalveolar crestal resorptionbone formationdrug delivery vehicle |
| spellingShingle | Rohini Naineni Vishali Ravi Dwijendra Kocherlakota Subbaraya Jammula Surya Prasanna Veerendranath Reddy Panthula Rekha Rani Koduganti Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial Journal of Clinical and Diagnostic Research alveolar crestal resorption bone formation drug delivery vehicle |
| title | Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial |
| title_full | Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial |
| title_fullStr | Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial |
| title_full_unstemmed | Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial |
| title_short | Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial |
| title_sort | effect of alendronate with β tcp bone substitute in surgical therapy of periodontal intra osseous defects a randomized controlled clinical trial |
| topic | alveolar crestal resorption bone formation drug delivery vehicle |
| url | https://jcdr.net/articles/PDF/8365/20965_CE(EK)_F(AK)_PF1(NEAK)_PFA(AK)_PF2(PAG).pdf |
| work_keys_str_mv | AT rohininaineni effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial AT vishaliravi effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial AT dwijendrakocherlakotasubbaraya effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial AT jammulasuryaprasanna effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial AT veerendranathreddypanthula effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial AT rekharanikoduganti effectofalendronatewithbtcpbonesubstituteinsurgicaltherapyofperiodontalintraosseousdefectsarandomizedcontrolledclinicaltrial |